A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib

Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriel, Joseph Gabriel, Kapila, Aaysha, Gonzalez-Estrada, Alexei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446100/
https://www.ncbi.nlm.nih.gov/pubmed/28589155
http://dx.doi.org/10.1177/2324709617711463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446100/
https://www.ncbi.nlm.nih.gov/pubmed/28589155
http://dx.doi.org/10.1177/2324709617711463

Ejemplares similares